[Asia Economy Reporter Seo So-jung] Samsung Bioepis (CEO Go Han-seung) announced on the 2nd that it has started Phase 1 clinical trials of 'SB17', a biosimilar (biopharmaceutical copy) of the autoimmune disease treatment 'Stelara'.
According to the global clinical trial information website 'ClinicalTrials', Samsung Bioepis began Phase 1 clinical trials in February 2021 in France, involving 201 healthy volunteers to evaluate the pharmacokinetics, safety, and immunogenicity of SB17.
Stelara is an autoimmune disease treatment marketed by Johnson & Johnson in the United States for conditions such as psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Its global annual sales reached approximately 8.4 trillion KRW last year.
A Samsung Bioepis official said, "At the time of our 9th anniversary, we have started clinical trials for our 10th biosimilar pipeline," adding, "We will continue to strive to provide treatment benefits through high-quality biopharmaceuticals to more patients in the future."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
